La santé et la fertilité des vaches laitières sont au cœur des préoccupations de la filière professionnelle dans un objectif d’efficience, de quantité et de qualité de la production de lait. La mise en place d’une lactation performante se superpose aux profonds changements hormonaux et métaboliques de la période postpartum, se traduisant par une balance énergétique négative. Les conséquences en sont souvent une altération de la fertilité et une immunodépression qui accroit la susceptibilité aux pathologies. Dans les élevages, il existe encore une grande variabilité d’état général et de performances chez les vaches laitières malgré la sélection génomique. Il est proposé que des modifications de la méthylation de l’ADN puissent contribuer à cette variabilité phénotypique individuelle. En effet, la méthylation de l’ADN, en tant que processus épigénétique, est impliquée dans la régulation transcriptionnelle des gènes, et présente une certaine plasticité face aux contraintes environnementales. Nous avons fait l’hypothèse que des signatures épigénétiques portées par les cellules du sang, pourraient refléter l’état de santé des vaches et pourraient être modifiées en réponse à différents facteurs intrinsèques (parité, stades physiologiques…) et aux contraintes environnementales. Ces signatures ont été recherchées dans une population de cellules du sang particulière : les monocytes. Ces cellules, accessibles par prélèvements sanguins et purification en présence d’un anticorps spécifique, constituent la première ligne de réponse d’immunité innée face aux infections aigües participant à la dégradation de l’état de santé des vaches en postpartum. Pour tester l’hypothèse de signatures épigénétiques monocytaires, une analyse du méthylome par « Reduced Representation Bisulfite Sequencing », (RRBS) dans diverses situations d’élevage a été réalisée. En utilisant des ADN génomiques de vaches incluses dans plusieurs protocoles, 22 banques ont été construites et séquencées. Leur analyse a été réalisée en utilisant un pipeline d’analyses bioinformatique et biostatistique développé au laboratoire.En moyenne 1 250 000 CpG sont pris en considération et permettent l’identification et la localisation de cytosines différentiellement méthylées (DMC) : i) 27143 DMC en comparant les méthylomes de différents types cellulaires (monocytes versus fibroblastes et PBMC) ii) 4788 DMC en réponse à un challenge nutritionnel basé sur la distribution du complément alimentaire GENIAL®, fabriqué et distribué en élevage par nos partenaires PILARDIERE et XR-Repro. iii) 2615 et 4616 DMC en réponse au challenge infectieux pour le groupe de vaches témoins et le groupe en restriction alimentaire respectivement (protocole coordonné par Christine Leroux et José Pires (RUMINFLAME, INRA, Theix) combinant une restriction alimentaire et un challenge immunitaire, par injection de LipoPolySaccharide). iv) 4420 DMC issues de la comparaison entre méthylomes de vaches à génome constant (issues du transfert nucléaire, clones) et de vaches à génome variable mais de même âge et élevées dans les mêmes conditions que les clones. Pour certaines régions différentiellement méthylées (DMR) ciblant le promoteur de gènes, le statut de méthylation a été confirmé par conversion bisulfite et pyroséquençage. L’expression des gènes associés a été étudiée. Une anti corrélation significative est observée entre méthylation et expression signant la fonctionnalité de ces régions.En comparant les 11 méthylomes monocytaires, il est montré que 21% des CpG sont extrêmement stables et ne présentent qu’une faible variation de méthylation entre échantillons ( 20%). L’ensemble de ces informations peut être pris en considération pour la conception d’un outil d’épigénotypage. A l’avenir, il serait aussi possible d’utiliser cet outil en routine afin d’appréhender les variations du méthylome monocytaire dans différentes conditions d’élevage. / In dairy breeding, the health and fertility of cows are the main concern with the aims to maintain milk quantity and quality and to reduce the interval between calving in a high competitive economical context. Postpartum period is marked by major hormonal and metabolic changes that affect productivity, immune responses and fertility. The consequences of immune response deterioration are an increasing susceptibility to diseases (mastitis, metritis, endometritis…). Genomic selection in livestock improves the performance of the population but does not exclude phenotypic variability at the level of livestock and the individual. It is proposed that DNA methylation could contribute to this individual phenotype variability. Indeed, DNA methylation is an epigenetic process involved in transcriptional regulation of genes displaying certain plasticity in front of environmental constraints.We assumed the epigenetic signatures carried by blood cells, could reflect overall health and could be modified in response to intrinsic factors (parity, stages …) and to environmental changes. These signatures were researched in a particular blood cells subpopulation: the monocytes. These cells, obtained by blood sampling and purification with a specific antibody, are the first line of defense against acute infections participating in health status deterioration of postpartum cows.To test the monocyte epigenetic signatures hypothesis, monocyte methylome were analyzed by « Reduced Representation Bisulfite Sequencing » (RRBS), in various breeding conditions. Using genomic DNA form cows included in several protocols, 22 libraries were constructed and sequenced. Their analyses were accomplished using a « homemade » pipeline which integrates bioinformatics and biostatistics analyses. On average, 1 250 000 CpGs were analyzed in order to identify differentially methylated cytosines (DMCs): i) 27143 DMC by comparison between different cells types (monocytes versus fibroblasts and PBMC) ii) 4788 DMCs in response to nutritional challenge based on the dietary supplement, GENIAL®, produced and distributed in breeding by our partner PILARDIERE and XR-Repro (in collaboration with Marion Boutinaud, INRA, Rennes). iii) 2615 and 4616 DMCs in response to infectious challenge with LipoPolySaccharide injection for control cows group fed normal diet and for dietary restriction cows group, respectively (collaboration with Christine Leroux and José Pires, RUMINFLAME, INRA, Theix; and Gilles Foucras (ENVT, Toulouse)). iv) 4420 DMCs from the comparison between constant genomic cow (Somatic cell nuclear transfer, clones) and variable genomic cows but with the same age and raised in the same conditions than clones.From DMCs, we identified differentially methylated regions (DMRs) defined as region with at least 3 DMCs inside 100 bp. For some DMRs targeting gene promoter, the methylation status was validated by bisulfite conversion and pyrosequencing. Gene associated expression were also investigated. A significant negative correlation has been observed between methylation and expression, highlighting the functional relevance of these DMRs in gene transcription control.By comparing the 11 monocyte methylomes, 21% of CpGs present a remarkable constant methylation level with weak variability between samples (20%).Taking together, these data can provide a list of relevant DMCs for an epigenetic tool conception. In the future, it would be possible to use this tool for a routine analysis in order to grasp monocyte methylome variations in different breeding management.

La spermatogénèse, processus de production des gamètes mâles, représente un modèle physiologique pertinent pour l’étude de la dynamique de la chromatine. En effet, une réorganisation drastique du génome est observée en fin de spermatogénèse, lors des étapes post-méiotiques du développement de la lignée germinale mâle. Ces réorganisations visent d’une part à compacter le génome afin de le protéger avant et lors de la fécondation et d’autre part à établir un épigénome mâle spécifique nécessaire pour le développement embryonnaire précoce. La chromatine organisée en nucléosomes est alors totalement remaniée de manière à ce que les protamines remplacent les histones dans les spermatozoïdes. Cette réorganisation est initiée par une vague d’acétylation des histones à l’échelle du génome, suivie par un remplacement massif des histones par de petites protéines basiques, les protéines de transition et les protamines. Les mécanismes moléculaires responsables de cette réorganisation de la chromatine sont très mal connus. Mon travail de thèse vise à explorer ces mécanismes en utilisant une approche d’invalidation de gènes chez la souris correspondant à des acteurs épigénétiques exprimés spécifiquement en post-méiose : le facteur nucléaire Nut (Nuclear protein in Testis) et le variant de l’histone H2A, H2A.L.2. Nous avons démontré que la protéine Nut recrute l’acétyltransferase p300 et induit l’hyperacétylation de l’histone H4 précisément au niveau des résidus lysines en position 5 et 8. Cette acétylation est nécessaire à l’interaction avec le premier bromodomaine de Brdt initiant le processus de remplacement des histones par les protamines. Ainsi, le facteur Nut est l’élément majeur de la vague d’acétylation des histones. Nous avons également mis en évidence le rôle crucial de H2A.L.2 dans “ l’ouverture ” de la structure du nucléosome permettant ainsi son invasion par les protéines de transition. Ces protéines vont à leur tour générer une plateforme pour le recrutement et la maturation des protamines et induire la formation de structures transitoires avant l’étape de compaction finale du génome des spermatozoïdes matures. Ces études nous ont ainsi permis d’établir pour la première fois un modèle moléculaire cohérent permettant de comprendre la programmation épigénétique post-méiotique du génome mâle et son impact sur la fertilité masculine. / Spermatogenesis, the process of producing male gametes, represents a relevant physiological model for the study of chromatin dynamics. Indeed, a drastic reorganization of the genome is observed at the end of spermatogenesis, during post-meiotic stages of the development of the male germ cells. These reorganizations are intended both to compact the genome to protect it before and during fertilization and to establish a specific male epigenome necessary for early embryonic development. In spermatozoa, during these post-meiotic stages, chromatin is completely reorganized so that the protamines replace the histones. This reorganization is initiated by a wave of genome-wide histone acetylation, followed by massive replacement of histones by small basic proteins, transition proteins and protamines. The molecular mechanisms responsible for this reorganization of the genome remain very poorly known today. My thesis aims to explore these mechanisms by using gene inactivation in mouse of epigenetic actors specifically expressed in post-meiotic germ cells : the nuclear factor Nut (Nuclear protein in Testis) and the histone H2A variant, H2A.L.2. We have demonstrated that the Nut protein interacts and stimulates the p300 acetyltransferase activity and induces the hyperacetylation of histone H4 precisely on the lysine residues at 5 and 8 positions. This acetylation is necessary for the interaction with the first bromodomain of Brdt initiating the process of histone replacement by protamines. Thus, the Nut factor is the main element of the histone acetylation wave. We have also deciphered the crucial role of H2A.L.2 in the “opening ” of nucleosomal structures in post-meiotic germ cells thus allowing its invasion by the transition proteins. These transition proteins will in turn generate a platform for the recruitment and maturation of protamines and induce the formation of transient structures before the final compaction of the mature sperm genome. These studies allowed us to establish for the first time a coherent molecular model for understanding the post-meiotic epigenetic programming of the male genome and its impact on male fertility.

京都大学 / 0048 / 新制・課程博士 / 博士(理学) / 甲第19917号 / 理博第4217号 / 新制||理||1606(附属図書館) / 33003 / 京都大学大学院理学研究科生物科学専攻 / (主査)教授 工藤 洋, 教授 長谷 あきら, 教授 鹿内 利治 / 学位規則第4条第1項該当 / Doctor of Science / Kyoto University / DGAM

京都大学 / 0048 / 新制・論文博士 / 博士(医学) / 乙第13139号 / 論医博第2139号 / 新制||医||1026(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 松田 道行, 教授 中川 一路, 教授 原田 浩 / 学位規則第4条第2項該当 / Doctor of Medical Science / Kyoto University / DFAM

No description available.

Le neuroblastome pédiatrique est un des cancers extra-crâniens des plus fréquents chez les enfants. Malgré une amélioration du taux de survie avec les thérapies actuellement disponibles, les stades avancés de neuroblastome ou en rechute présentent un très mauvais pronostic. De nouvelles approches thérapeutiques doivent donc être développées afin d'augmenter la survie des patients. Une de ces approches est la thérapie épigénétique. Le neuroblastome, comme plusieurs autres cancers pédiatriques, contient plusieurs altérations épigénétiques au niveau de la méthylation de l'ADN et des modifications des histones. Lors d'un criblage de médicaments déjà approuvés par la FDA, nous avons découvert quelques molécules ayant des caractéristiques de médicaments épigénétiques jusqu’alors jamais découvertes. Notre étude cherche donc à démontrer l'efficacité de ces molécules dans le traitement de lignées cellulaires de neuroblastome. Suite à des tests préliminaires, une des molécules approuvées par la FDA s'est démarquée : le disulfirame, un médicament approuvé pour le traitement de l’alcoolisme chronique. Nous avons donc traité des lignées cellulaires de neuroblastomes (IMR-32, N91, SK-N-DZ, SK-N-SH et SK-N-AS ) pendant 48 heures avec du disulfirame à des concentrations pertinentes sur le plan clinique (10nM à 50 µM). Nos résultats démontrent une inhibition de croissance de 50 % (IC50) d'environ 80 nM pour les lignées cellulaires testées. De plus, après analyse par cytométrie de flux, on observe un blocage du cycle cellulaire en G2/M. Nous avons également observé une diminution du facteur de transcription MYCN ainsi qu’une baisse d’acétylation de plusieurs marques d’histones (H3K9ac, H3K14ac, H3K27ac). Une analyse par séquençage d'ARN a confirmé le bloc en G2/M par une baisse d'expression de gènes associés à cette phase ainsi que la diminution de MYCN par une baisse de gènes cible de MYC. Des travaux sont en cours afin de déterminer le mécanisme d’action du disulfirame. Cette recherche permettra d’évaluer l’efficacité du disulfirame dans le traitement du neuroblastome / Pediatric neuroblastoma is one of the most common extracranial cancer in children. Despite an improvement in survival with the currently available therapies, neuroblastoma with an amplification of the transcription factor MYCN has a very poor prognosis. New therapeutic approaches must be developed to increase the survival of patients. One such approach is epigenetic drug therapy. Neuroblastoma, like many other pediatric cancers, contains several epigenetic alterations at the level of DNA methylation and histone modifications. In a screening of FDA-approved drugs, we discovered some molecules having characteristics of epigenetic drugs that were unknown until now. Our study seeks to demonstrate the efficacy of these molecules in the treatment of neuroblastoma cell lines. Following preliminary tests, one of the molecules approved by the FDA stood out: disulfiram, a medication approved for the treatment of chronic alcoholism. We treated neuroblastoma cell lines (MYCN amplified: IMR-32, N91 and SK-N-DZ; MYCN non-amplified: SK-N-AS and SK-N-SH) for 48 hours with disulfiram at clinically relevant concentrations (from 10 nM to 20 µM). Our results demonstrate a 50% growth inhibition (IC50) of 80nM for the cell lines tested. In addition, after analysis by flow cytometry, we found a cell cycle block in G2/M. RNA sequencing also revealed that disulfiram affects a many genes (downregulated n=508, upregulated n=207). We also observed a decrease in the transcription factor MYCN and a reduction in acetylation of several histone marks by Western blot’s analysis. Further studies are underway to determine the mechanism of action of disulfiram. This study shows the potential of disulfiram in the treatment of neuroblastoma.

The self-organisation of cells into complex tissues relies on the tight regulation of molecular processes governing their behaviour. Understanding these processes is a central questions in cell biology. In recent years, technological breakthroughs in single-cell sequencing experiments have enabled us to probe these processes with unprecedented molecular detail. However, biological function relies on collective processes on the mesoscopic and macroscopic scale, which do not necessarily obey the rules that govern it on the microscopic scale. Insights from these experiments on how collective processes determine cellular behaviour consequently remain severely limited. Methods from nonequilibrium statistical physics provide a rigorous framework to connect microscopic measurements to their mesoscopic or macroscopic consequences. In this thesis, by combining for the first time the possibilities of single-cell technologies and tools from nonequilbrium statistical physics, we develop theoretical frameworks that overcome these conceptual limitations. In particular, we derive a theory that maps measurements along the linear sequence of the DNA to mesoscopic processes in space and time in the cell nucleus. We demonstrate this approach in the context of the establishment of chemical modifications of the DNA (DNA methylation) during early embryonic development. Drawing on sequencing experiments both in vitro and in vivo, we find that the embryonic DNA methylome is established through the interplay between DNA methylation and 30-40 nm dynamic chromatin condensates. This interplay gives rise to hallmark scaling behaviour with an exponent of 5/2 in the time evolution of embryonic DNA methylation and time dependent, scale-free connected correlation functions, both of which are predicted by our theory. Using this theory, we successfully identify regions of the DNA that carry DNA methylation patterns anticipating cellular symmetry breaking in vivo. The primary layer determining cell identity is gene expression. However, read-outs of gene-expression profiling experiments are dominated by systematic technical noise and they do not provide “stochiometric” measurements that allow experimental data to be predicted by theories. Here, by developing effective spin glass methods, we show that the macroscopic propagation of fluctuations in the concentration of mRNA molecules gives direct information on the physical mechanisms governing cell states, independent of technical bias. We find that gene expression fluctuations may exhibit glassy behaviour such that they are long-lived and carry biological information. We demonstrate the biological relevance of glassy fluctuations by analysing single-cell RNA sequencing experiments of mouse neurogenesis. Taken together, we overcome important conceptual limitations of emerging technologies in biology and pioneer the application of methods from stochastic processes, spin glasses, field and renormalization group theories to single-cell genomics.

No description available.

MicroRNAs (miRNAs) are small non-coding RNAs that post-transcriptionally regulate gene expression via inhibiting mRNA translation or degrading mRNA. Since the discovery of miRNAs, dysregulated miRNAs have been identified in human patients with various diseases. Moreover, the role of miRNAs in biological processes, including immune homeostasis and autoimmunity pathogenesis, has been widely investigated. Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease that causes systemic damage to multiple organs and is characterized by the production of pathogenic autoimmune antibodies. In previous work in my lab, a set of commonly upregulated miRNAs in splenic lymphocytes of three lupus-prone mouse models was identified, including the miR-183-96-182 cluster (miR-183C) and miRNAs located at DLK1-DIO3 region. The work presented in this dissertation focuses on comparing the dysregulation pattern of miRNAs from different cell sources of lupus-prone mice and investigating the potential role of miR-183C in the pathogenesis of SLE and inflammation. The first goal was to test whether dysregulated miRNAs initially identified in the spleen of MRL/lpr mice, a standard model for SLE, is also reflected in the peripheral blood mononuclear cells (PBMCs) as PBMC is the primary source of lymphocytes in human patients. In MRL/lpr mice, we found that dysregulated miRNAs in PBMCs were overall comparable to those identified in the splenic lymphocytes. Further, comparing dysregulated miRNAs between mice and humans showed a similarity in the dysregulation of miRNAs in PBMCs of murine and human lupus. Among the upregulated miRNAs, the expression of three miRNAs of miR-183C was found to be commonly upregulated. To investigate the role of miR-183C, we developed miR-183C in CD2+ cells of C57BL/6 Faslpr/lpr (miR-183C-/-B6/lpr) mice. In miR-183C-/-B6/lpr mice, we observed a significantly reduced level of anti-dsDNA in the serum and IgG immunocomplex deposition in the kidney. Importantly, in vitro inhibition of miR-183C in activated splenic lymphocytes led to reduced production of the proinflammatory cytokine, IFN, and Foxo1, a transcription factor that is a target of miR-183C miRNAs. I also tested for miRNA changes in C57BL/6 Faslpr/lpr mice with conditional deletion of Early Growth Response-2 (EGR2) (Egr2-/- B6/lpr), another knockout mouse developed in our laboratory. Egr2 has recently been shown to regulate immunity and autoimmunity and play a role in lupus. An unexpected observation is that Egr2-/-B6/lpr mice had significantly reduced expression of a group of lupus-related miRNAs that are located at the genomic imprinted DLK1-DIO3 locus. Given that the upregulation of DLK1-DIO3 miRNAs in lupus is subjected to DNA methylation regulation and that the epigenetic regulatory role of EGR2 is emerging in recent studies, reduced representative bisulfite sequencing (RRBS) was performed to evaluate the methylation changes induced by Egr2 deletion. Global DNA hypomethylation and methylation changes at specific sites at DLK1-DIO3 region were noticed in CD4+ T cells of Egr2-/-B6/lpr mice. Overall, our research suggested a therapeutic effect of inhibiting the miR-183C expression on SLE. The interplay between epigenetic factors could help expand the possibility of controlling epigenetic regulators in autoimmune disease treatment. / Doctor of Philosophy / Systemic lupus erythematosus (SLE) is an autoimmune disease that causes damage to multiple organs. Same with other autoimmune diseases, the exacerbated immune reaction to self-antigen and auto-reactive adaptive immune cells were described in SLE. Currently, the treatment of lupus mainly uses immunosuppressive drugs to inhibit the global immune reaction. Thus, the innovative drug is desperately needed for SLE patients. MicroRNAs (miRNAs) are small RNAs that inhibit the expression of genes by binding to mRNAs in a complimentary manner. Since the discovery of the first microRNA, the pivotal role of microRNAs in immunity and autoimmunity was vigorously investigated. Our lab was the first to describe a set of miRNAs that are commonly upregulated in three murine lupus models. Among these miRNAs, miR-183, miR-96, and miR-182 belong to the miR-183-96-182 cluster (miR-183C). The aim of the study in this dissertation focused on illuminating the dysregulation pattern of miRNAs in different cell sources in the murine lupus model and the role of miR-183C in the pathogenesis of SLE. We found that miRNAs are similarly dysregulated in peripheral blood mononuclear cells and splenic lymphocytes of MRL/lpr mice. Then we conditionally knocked out the miR-183C in B6/lpr mice and investigated the effect of miR-183C loss on the pathogenesis of autoimmunity. Importantly, we found that the deletion of miR-183C led to a reduced production level of autoantibodies and ameliorated the deposition of immune complexes in the kidney. Moreover, the production of proinflammatory cytokines of splenic lymphocytes was regulated by miR-183C as well. Besides miR-183C, I also investigated the effect of early growth response 2 (EGR2), a transcription factor, on the expression of a set of lupus-related miRNAs and the methylation change at the genome location of these miRNAs. In summary, miR-183C can be a potential therapeutic target for lupus treatment while clinical human studies are needed to better clarify the effectiveness and efficiency.

付記する学位プログラム名: 京都大学卓越大学院プログラム「メディカルイノベーション大学院プログラム」 / 京都大学 / 新制・課程博士 / 博士(医科学) / 甲第24534号 / 医科博第148号 / 新制||医科||10(附属図書館) / 京都大学大学院医学研究科医科学専攻 / (主査)教授 寺田 智祐, 教授 川上 浩司, 教授 YOUSSEFIAN Shohab / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM